Abstract：
OBJECTIVE: To assess whether the use of selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, mirtazapine, venlafaxine or other antidepressants is associated with late elective termination of pregnancy.
METHODS: Case-control study using data from national registers.
METHODS: Denmark, Finland, and Norway during the period 1996-2007.
METHODS: A total of 14,902 women were included as cases and 148,929 women were included as controls.
METHODS: Cases were women with elective termination of pregnancy at 12-23 weeks of gestation. Controls continued their pregnancy and were matched with cases on key factors.
METHODS: Association between antidepressant use during pregnancy and elective termination of pregnancy at 12-23 weeks of gestation for fetal anomalies, or for maternal ill health or socio-economic disadvantage.
RESULTS: At least one prescription of antidepressants was filled by 3.7% of the cases and 2.2% of the controls. Use of any type of antidepressant was associated with elective termination of pregnancy for maternal ill health or socio-economic disadvantage (odds ratio, OR 2.3; 95% confidence interval, 95% CI 2.0-2.5). Elective termination of pregnancy for fetal anomalies was associated with the use of mirtazapine (OR 2.2, 95% CI 1.1-4.5). There was no association between the use of any of the other antidepressants and elective termination of pregnancy for fetal anomalies.
CONCLUSIONS: The use of any type of antidepressants was associated with elective termination of pregnancy at 12-23 weeks for maternal ill health or socio-economic disadvantage, but not with terminations for fetal anomalies. Further studies need to confirm the findings concerning mirtazapine and termination of pregnancy for fetal anomalies.
METHODS: Case-control study using data from national registers.
METHODS: Denmark, Finland, and Norway during the period 1996-2007.
METHODS: A total of 14,902 women were included as cases and 148,929 women were included as controls.
METHODS: Cases were women with elective termination of pregnancy at 12-23 weeks of gestation. Controls continued their pregnancy and were matched with cases on key factors.
METHODS: Association between antidepressant use during pregnancy and elective termination of pregnancy at 12-23 weeks of gestation for fetal anomalies, or for maternal ill health or socio-economic disadvantage.
RESULTS: At least one prescription of antidepressants was filled by 3.7% of the cases and 2.2% of the controls. Use of any type of antidepressant was associated with elective termination of pregnancy for maternal ill health or socio-economic disadvantage (odds ratio, OR 2.3; 95% confidence interval, 95% CI 2.0-2.5). Elective termination of pregnancy for fetal anomalies was associated with the use of mirtazapine (OR 2.2, 95% CI 1.1-4.5). There was no association between the use of any of the other antidepressants and elective termination of pregnancy for fetal anomalies.
CONCLUSIONS: The use of any type of antidepressants was associated with elective termination of pregnancy at 12-23 weeks for maternal ill health or socio-economic disadvantage, but not with terminations for fetal anomalies. Further studies need to confirm the findings concerning mirtazapine and termination of pregnancy for fetal anomalies.
摘要：
目的：评估使用选择性5-羟色胺再摄取抑制剂（SSRIs）是否，三环抗抑郁药，米氮平,文拉法辛或其他抗抑郁药与晚期选择性终止妊娠有关。
方法：使用国家登记册数据的病例对照研究。
方法：丹麦，芬兰,和挪威在1996-2007年期间。
方法：共纳入14,902名妇女作为病例，148,929名妇女作为对照。
方法：病例为妊娠12-23周选择性终止妊娠的妇女。对照组继续怀孕，并在关键因素上与病例相匹配。
方法：妊娠期间使用抗抑郁药与妊娠12-23周时胎儿畸形选择性终止妊娠之间的关联，或孕产妇健康不良或社会经济不利。
结果：3.7%的病例和2.2%的对照组至少有一个抗抑郁药处方。任何类型的抗抑郁药的使用都与选择性终止妊娠有关，因为孕产妇的健康或社会经济不利（优势比，OR2.3；95%置信区间，95%CI2.0-2.5）。胎儿畸形选择性终止妊娠与使用米氮平相关(OR2.2,95%CI1.1-4.5)。任何其他抗抑郁药的使用与胎儿畸形的选择性终止妊娠之间没有关联。
结论：任何类型的抗抑郁药的使用与12-23周时因产妇健康不良或社会经济不利而选择性终止妊娠有关，但不能因为胎儿异常而终止妊娠.进一步的研究需要确认有关米氮平和胎儿畸形终止妊娠的发现。
方法：使用国家登记册数据的病例对照研究。
方法：丹麦，芬兰,和挪威在1996-2007年期间。
方法：共纳入14,902名妇女作为病例，148,929名妇女作为对照。
方法：病例为妊娠12-23周选择性终止妊娠的妇女。对照组继续怀孕，并在关键因素上与病例相匹配。
方法：妊娠期间使用抗抑郁药与妊娠12-23周时胎儿畸形选择性终止妊娠之间的关联，或孕产妇健康不良或社会经济不利。
结果：3.7%的病例和2.2%的对照组至少有一个抗抑郁药处方。任何类型的抗抑郁药的使用都与选择性终止妊娠有关，因为孕产妇的健康或社会经济不利（优势比，OR2.3；95%置信区间，95%CI2.0-2.5）。胎儿畸形选择性终止妊娠与使用米氮平相关(OR2.2,95%CI1.1-4.5)。任何其他抗抑郁药的使用与胎儿畸形的选择性终止妊娠之间没有关联。
结论：任何类型的抗抑郁药的使用与12-23周时因产妇健康不良或社会经济不利而选择性终止妊娠有关，但不能因为胎儿异常而终止妊娠.进一步的研究需要确认有关米氮平和胎儿畸形终止妊娠的发现。
